| abstract |
The present invention relates to crystalline and anhydrous solid state forms of hydrobromide salts of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl) amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (compound 1), pharmaceutical compositions comprising said forms and methods of preparation. Said forms possess acceptable properties such as chemical stability, thermal stability, solubility, hygroscopicity and/or particle size; compoundability, such as yield, rejection of impurities during crystallization, filtration properties, drying properties, and grinding properties; and viability of the formulation, having an acceptable balance of said properties, being able to prepare pharmaceutically acceptable solid dosage forms, being useful in the treatment of cancer. |